Oxford BioMedica/Sanofi Make Headway With FDA On TroVax Cancer Vaccine
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After facing a setback with the therapeutic cancer vaccine TroVax in July, partners Oxford BioMedica and Sanofi-Aventis are reaffirming their commitment to develop the vaccine for the treatment of renal cancer and potentially colorectal cancer following a meeting with FDA